BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the completion of a U.S. clinical study, conducted by Ora, Inc. Andover, MA, des…
FDA approves anti-allergy agent from Alcon
The U.S. Food and Drug Administration has granted U.S. marketing approval to Pazeo, a solution for ocular allergy itch relief from Alcon. Pazeo (olopatadine HCl ophthalmic solution) 0.7% is a once-daily drop designed to relieve itching related to aller…
National Centre for Healthcare Photonics to be located in North East of England
One of the most interesting and fastest developing areas in healthcare is the use of light to diagnose and treat medical conditions and illnesses, collectively known as Healthcare Photonics. It includes a range of new phototherapies as well as bio-medi…
Iridex receives FDA clearance for Cyclo G6 Laser System
The U.S. Food and Drug Administration issued 510(k) clearance for the Cyclo G6 Laser System to treat glaucoma, according to a press release from Iridex.The laser system is designed to treat patients diagnosed with multiple stages of glaucoma using Micr…
Are Treat-and-Extend Protocols Effective in AMD?
A 2-year analysis of treat-and-extend protocols provides important information on anti-VEGF therapy in AMD, building on earlier pivotal trials. Medscape Ophthalmology
IRIDEX Cyclo G6 Laser System receives FDA clearance for treatment of glaucoma
IRIDEX Corporation today announced that it has received clearance from the U.S. Food and Drug Administration to market its first laser system designed solely for use in treating glaucoma and its symptoms. Specifically, the Company was granted 510(k) cl…